|Biodegradable stent proves non-inferior to drug-eluting stent|
The IVUS substudy showed somewhat less neointimal hyperplasia over nine months with the Orsiro stent (0.16) than the Xience stent (0.43, p=0.043) with 100% stent apposition. Similarly, neointimal area as assessed by OCT at nine months was somewhat ...
Medical Xpress - Tue, 21 May 2013 14:27
|CE Mark approval for benign prostatic hyperplasia|
Cook Medical has received CE Mark approval for its PVA Foam Embolization Particles to be used for the treatment of symptomatic benign prostatic hyperplasia (BPH). The product will be shown at this year's Global Embolization Symposium and Technologies ...
Hospital Healthcare Europe - Thu, 02 May 2013 02:20
|Nymox completes patient enrollment in Phase 3 BPH study of NX-1207|
Nymox Pharmaceutical has completed patient enrollment in final pivotal US Phase 3 benign prostatic hyperplasia (BPH) study of NX-1207. Nymox CEO Paul Averback said, "Final completion of enrollment in this last major pivotal U.S. study is an important ...
Pharmaceutical Business Review - Mon, 06 May 2013 03:07
|Nymox Reports on Symposium and Panel Discussion on NX-1207 at American ...|
Wall Street Journal (press release) - Mon, 06 May 2013 06:06
|Lumenis Unveils New Simulator to Train Urologists on Gold Standard HoLEP ...|
YOKNEAM, ISRAEL, May 02, 2013 (Marketwired via COMTEX) -- Lumenis Ltd., will unveil a new surgical teaching simulator for Holmium Laser Enucleation of the Prostate (HoLEP), which is designed to dramatically shorten the surgical learning curve for ...
MarketWatch (press release) - Thu, 02 May 2013 07:15
|Researchers endorse more herbs for prostate cancer treatment|
BENIGN prostatic hyperplasia (BPH) is the most common benign tumour of the adult male and men with Lower Urinary Tract Symptoms (LUTS) from clinical BPH constitute a great percentage of patients seen in urology clinics. Its treatment does constitute a ...
The Guardian Nigeria - Thu, 02 May 2013 11:17
|Nephrology And Urology Devices Market (Dialysis Equipment, Lithotripsy ...|
The nephrology and urology devices market report analyzes current dynamics and trends in the global nephrology and urology devices market for the period 2010 - 2018 and gives a forecast of the market from 2012 - 2018, considering 2011 as the base year.
MarketWatch (press release) - Tue, 30 Apr 2013 05:09
|Daiichi Sankyo launches dysuria therapy in China|
Daiichi Sankyo Pharmaceutical has launched silodosin for the treatment of dysuria associated with benign prostatic hyperplasia in China. Silodosin works by inhibiting the alpha 1A-adrenergic receptor and relieving tension in the prostate, lessening ...
Pharmaceutical Business Review - Mon, 22 Apr 2013 01:56
|Daiichi Sankyo Launches Silodosin for the Treatment of Dysuria in China|
European Investor (subscription) - Sun, 21 Apr 2013 19:30
|Head-to-head study shows GreenLight XPS laser therapy equally safe ...|
Data demonstrate that treatment for Benign Prostatic Hyperplasia (BPH) with GreenLight XPS laser therapy with MoXy fiber, instead of transurethral resection of the prostate (TURP), results in significantly shorter hospitalization, catheterization, and ...
pharmabiz.com - Tue, 07 May 2013 22:34